论文部分内容阅读
:[目的]探索α 双炔失碳酯对人原发卵巢癌组织的作用及其与E2 水平、ER表达之间的关系。[方法]应用MTT法检测α 双炔失碳酯对19例人原发卵巢癌组织的生长调节作用 ;采用免疫组化ABC法测定19例石蜡组织ER含量 ;术前抽取静脉血 ,酶标法测E2 水平。[结果](1)100μmol/Lα 双炔失碳酯作用72小时后 ,肿瘤细胞生长抑制率大于30%者共7例(敏感组) ,占36 8% ;生长抑制率小于30%者共12例(不敏感组) ,该抑制作用与病人年龄、绝经与否、临床期别、分化程度、病理类型等无明显相关。(2)敏感组E2 的平均水平为(45 07±46 84)pg/ml,不敏感组E2 的平均水平(25 77±26 41)pg/ml(P>0 05)。(3)ER阴性共7例 ,抑制率大于30%者占14 3%(1/7例) ,ER阳性共12例 ,抑制率大于30%占50%(6/12例)(P>0 05)。[结论]α 双炔失碳酯对原发卵巢癌细胞有一定抑制作用。ER阳性 ,E2 水平高的患者对α 双炔失碳酯的敏感性有高于ER阴性 ,E2 水平低的患者的趋势
: [Objective] To explore the effect of α-anordrin on human primary ovarian cancer and its relationship with E2 level and ER expression. [Method] MTT assay was used to detect the growth regulatory effect of α-anordrin on 19 human primary ovarian cancer tissues. The immunohistochemical ABC method was used to determine the ER content of 19 paraffin-embedded tissues. Venous blood and enzyme-linked immunosorbent assay Measured E2 level. [Results] (1) After 72 hours of 100μmol / L α-anordrin treatment, the tumor cell growth inhibition rate was more than 30% (sensitive group), accounting for 36.8%; the growth inhibition rate was less than 30%, a total of 12 Cases (insensitive group), the inhibition and patient age, menopause or not, clinical stage, the degree of differentiation, pathological type, etc. no significant correlation. (2) The average level of E2 in the sensitive group was (45 07 ± 46 84) pg / ml, and the average level of E2 in the non-sensitive group was 25 77 ± 26 41 pg / ml (P 0.05). (3) There were 7 cases with ER negative, the inhibition rate was more than 30%, accounting for 14 3% (1/7 cases), 12 cases were ER positive, the inhibition rate was more than 30% (6/12 cases) 05). [Conclusion] α-anordrin ester has some inhibitory effects on primary ovarian cancer cells. Patients with a positive ER and E2 level had a higher susceptibility to alpha-anordrin than those with a negative ER and a low E2 level